An anonymous director reports

KITS ANNOUNCES TSX ACCEPTANCE OF NORMAL COURSE ISSUER BID

The Toronto Stock Exchange has accepted Kits Eyecare Ltd.'s notice of intention to make a normal course issuer bid (NCIB) to purchase a portion of its common shares.

As of May 21, 2025, Kits had 32,006,915 issued and outstanding common shares. Pursuant to the NCIB, Kits may repurchase up to a maximum of 1,600,300 common shares, representing approximately 5 per cent of its issued and outstanding common shares. Purchases under the NCIB may be made through open-market transactions on the TSX and any alternative Canadian trading systems on which the common shares are traded, based on the prevailing market price. The total number of common shares the company is permitted to purchase is subject to a daily purchase limit of 10,958 common shares, representing 25 per cent of the average daily trading volume of common shares on the TSX calculated for the six-month period ended April 30, 2025, being approximately 43,835 common shares. However, the company may make one block purchase per calendar week that exceeds the daily repurchase restriction. Any common shares purchased under the NCIB will be cancelled.

Transactions under the NCIB will depend on future market conditions. Kits will initially retain discretion whether to make purchases under the NCIB and to determine the timing, amount and acceptable price of any such purchases, subject at all times to applicable TSX and other regulatory requirements. The period during which Kits is authorized to make purchases under the NCIB commences on June 3, 2025, and ends on June 2, 2026, or such earlier date on which the maximum number of common shares is purchased under the NCIB or the NCIB is terminated at the company's election. Under its previous NCIB that commenced on June 3, 2024, and will terminate on June 2, 2025, Kits is authorized to purchase a maximum of 1,572,505 common shares. To date, Kits has purchased a total of 25,000 common shares through the TSX at a weighted average price of $8.51 per common share.

Kits believes that share purchases pursuant to the NCIB will contribute to the facilitation of an orderly market and be in the best interests of the company and its shareholders. The NCIB provides the company with a capital allocation alternative with a view to long-term shareholder value. Kits's board of directors and management believe that, from time to time, the market price of the common shares does not reflect their underlying value and purchases of common shares for cancellation under the NCIB may provide an opportunity to enhance shareholder value.

The actual number of common shares that will be repurchased under the NCIB and the timing of any such purchases will be determined by Kits at management's discretion, subject to TSX rules and applicable securities laws. There cannot be any assurances as to how many common shares, if any, will ultimately be acquired by the company.

About Kits Eyecare Ltd.

Kits makes eyecare easy. Kits is a leading vertically integrated digital eyecare brand providing eyewear for eyes everywhere. Kits offers customers access to a vast selection of contact lenses and eyeglasses, including its own exclusive Kits-designed products, as well as a robust suite of on-line vision tools. The company's efficient digital platform, backed by its industry-leading manufacturing and designs, removes intermediaries, and enables Kits to offer great prices and deliver made-to-order personalized products with incredible care and accuracy. Kits is creating disruption in the industry by constantly pursuing cutting-edge technologies to enable the best customer experience, including on-line eyewear fitting tools and virtual try-on for glasses. Kits strives to delight its customers with its competitive prices, a convenient digital shopping experience, fast and reliable delivery options, and an unrelenting focus on earning its customers' lifelong trust.

We seek Safe Harbor.